The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma

Human Pathology

Volumn 37, Issue 5, 2006, Pages 562-568

  Rocha, Ana Sofia ^a   Risberg, Björn ^b   Magalhães, João ^c   Trovisco, Vitor ^a   de Castro, Inês Vieira ^d   Lazarovici, Philip ^e   Soares, Paula ^a,f   Davidson, Ben ^b   Sobrinho Simões, Manuel ^a,c,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF OSLO   (Norway)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^f University of Porto   (Portugal)

Author keywords

BRAF; p75 NTR; Papillary thyroid carcinoma; TrkA

Indexed keywords

B RAF KINASE; NEUROTROPHIN RECEPTOR; PROTEIN P75; PROTEIN RET; PROTEIN TYROSINE KINASE A;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FOLLICULAR CARCINOMA; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; PAPILLARY CARCINOMA; PAPILLARY THYROID CARCINOMA; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STATISTICAL SIGNIFICANCE; THYROID CARCINOMA;

ADENOCARCINOMA, PAPILLARY; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, NERVE GROWTH FACTOR; RECEPTOR, TRKA; THYROID GLAND; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646486717     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2005.12.016     Document Type: Article

References (30)

1. Soares P., Trovisco V., Rocha A.S., et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 22 (2003) 4578-4580
2. Tallini G. Molecular pathobiology of thyroid neoplasms. Endocr Pathol 13 (2002) 271-288
3. Teng K.K., and Hempstead B.L. Neurotrophins and their receptors: signaling trios in complex biological systems. Cell Mol Life Sci 61 (2004) 35-48
4. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
5. Melillo R.M., Castellone M.D., Guarino V., et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115 (2005) 1068-1081
6. Miller F.D., and Kaplan D.R. Neurotrophin signalling pathways regulating neuronal apoptosis. Cell Mol Life Sci 58 (2001) 1045-1053
7. Krygier S., and Djakiew D. The neurotrophin receptor p75NTR is a tumor suppressor in human prostate cancer. Anticancer Res 21 (2001) 3749-3755
8. Krygier S., and Djakiew D. Neurotrophin receptor p75(NTR) suppresses growth and nerve growth factor-mediated metastasis of human prostate cancer cells. Int J Cancer 98 (2002) 1-7
9. Davidson B., Reich R., Lazarovici P., et al. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83 (2004) 119-128
10. Descamps S., Pawlowski V., Revillion F., et al. Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 61 (2001) 4337-4340
11. Davidson B., Lazarovici P., Ezersky A., et al. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 7 (2001) 3457-3464
12. Russell J.P., Powell D.J., Cunnane M., et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 19 (2000) 5729-5735
13. Rosai J., Carcangiu M., and DeLellis R. Atlas of tumor pathology. 3rd series ed. (1993), Armed Forces Institute of Pathology, Washington (DC)
14. DeLellis R.A., Lloyd R., Heitz P., et al. Pathology and genetics. Tumours of endocrine organs. In: De Lellis R.A., Lloyd R.V., Hertz Ph.U., and Eng C. (Eds). WHO classification of tumours, World Health Organization classification of tumors (2004), IARC Press, Lyon
15. Hochman J., Park S.S., Lazarovici P., et al. Monoclonal antibodies to immunogenic lymphoma cell variants displaying impaired neoplastic properties: characterization and applications. J Natl Cancer Inst 82 (1990) 1821-1826
16. Trovisco V., Vieira de Castro I., Soares P., et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202 (2004) 247-251
17. Fluge O., Akslen L.A., Haugen D.R., et al. Expression of heregulins and associations with the ErbB family of tyrosine kinase receptors in papillary thyroid carcinomas. Int J Cancer 87 (2000) 763-770
18. Kato S., Kobayashi T., Yamada K., et al. Expression of erbB receptors mRNA in thyroid tissues. Biochim Biophys Acta 1673 (2004) 194-200
19. Ruco L.P., Stoppacciaro A., Ballarini F., et al. Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J Pathol 94 (2001) 4-8
20. Ivan M., Bond J.A., Prat M., et al. Activated ras and ret oncogenes induce overexpression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14 (1997) 2417-2423
21. Fanburg-Smith J.C., and Miettinen M. Low-affinity nerve growth factor receptor (p75) in dermatofibrosarcoma protuberans and other nonneural tumors: a study of 1,150 tumors and fetal and adult normal tissues. Hum Pathol 32 (2001) 976-983
22. Nikiforov Y.E. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13 (2002) 3-16
23. Castro P., Roque L., Magalhaes J., et al. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol 13 (2005) 235-238
24. Trovisco V., Soares P., Preto A., et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446 (2005) 589-595
25. Paez P.M., Missale C., Grubler Y., et al. Nerve growth factor and retinoic acid inhibit proliferation and invasion in thyroid tumor cells. Mol Cell Endocrinol 167 (2000) 99-106
26. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
27. Iwamoto S., Burrows R.C., Agoff S.N., et al. The p75 neurotrophin receptor, relative to other Schwann cell and melanoma markers, is abundantly expressed in spindled melanomas. Am J Dermatopathol 23 (2001) 288-294
28. Innominato P.F., Libbrecht L., and van den Oord J.J. Expression of neurotrophins and their receptors in pigment cell lesions of the skin. J Pathol 194 (2001) 95-100
29. Walch E.T., Albino A.P., and Marchetti D. Correlation of overexpression of the low-affinity p75 neurotrophin receptor with augmented invasion and heparanase production in human malignant melanoma cells. Int J Cancer 82 (1999) 112-120
30. Herrmann J.L., Menter D.G., Hamada J., et al. Mediation of NGF-stimulated extracellular matrix invasion by the human melanoma low-affinity p75 neurotrophin receptor: melanoma p75 functions independently of trkA. Mol Biol Cell 4 (1993) 1205-1216